Stevanato Group

Riverwater Partners' Small Cap Strategy initiated a position in Stevanato Group, arguing the stock sold off excessively after launches of oral GLP-1s despite sustained demand for injectable drug containment and delivery systems. The firm cites ongoing biologics approvals and diverse GLP-1 use cases that support continued need for injectables, and highlights an attractive entry valuation of 12.5x FY2026E EBITDA versus Stevanato's historic multiple of 20x and peers around 22–25x. Riverwater sees the dislocation as a buying opportunity within a quality-focused portfolio. » Więcej na finance.yahoo.com

Stevanato Group has received market approval in Europe for liraglutide-based combination products that use its Alina pen injector platform. Approved configurations are Alina 30 for diabetes therapies and Alina 50 for weight management. Alina is a disposable pen with variable dosing (0.01–0.75 ml), provides visual, auditory and tactile feedback, and is compatible with 3-ml glass cartridges meeting ISO standards. Production takes place in Stevanato Group’s Drug Delivery Systems business unit. » Więcej na de.investing.com

Stevanato Group reported Q1 2026 EPS of €0.11 and revenue of €273.6m, with EPS meeting guidance and revenue about 1.7% above forecasts. Growth was driven by the Biopharmaceutical and Diagnostic Solutions segment (+13%), while the Engineering segment shrank by 31%. Gross profit margin, operating margin and adjusted EBITDA improved, but higher tax rates weighed on net profitability. Despite the positive metrics, the shares fell about 4.05% in pre-market trading. » Więcej na de.investing.com